Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
LianBio Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update"
05/01/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "EXPLORER-CN Topline Data Results and Mavacamten China Commercial Opportunity Call May 1, 2023"
04/28/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/26/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
04/26/2023 8-K Quarterly results
04/21/2023 8-K Quarterly results
04/19/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/19/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/31/2023 4 Jahn Brianne (Chief Business Officer) has filed a Form 4 on LianBio
Txns: Granted 224,005 shares @ $0
03/31/2023 4 QIAN JIANG (SVP, China General Manager) has filed a Form 4 on LianBio
Txns: Granted 224,005 shares @ $0
03/31/2023 4 Wang Yizhe (CEO) has filed a Form 4 on LianBio
Txns: Granted 907,498 shares @ $0
03/31/2023 4 Larson Yi (CFO) has filed a Form 4 on LianBio
Txns: Granted 325,901 shares @ $0
03/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/28/2023 10-K Annual Report for the period ended December 31, 2022
03/27/2023 8-K Quarterly results
Docs: "LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy ongoing, with data expected mid-year 2023"
03/17/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/24/2023 4 Larson Yi (CFO) has filed a Form 4 on LianBio
Txns: Granted 464,099 options to buy @ $2.66, valued at $1.2M
01/24/2023 4 Jahn Brianne (Chief Business Officer) has filed a Form 4 on LianBio
Txns: Granted 318,995 options to buy @ $2.66, valued at $848.5k
01/24/2023 4 QIAN JIANG (SVP, China General Manager) has filed a Form 4 on LianBio
Txns: Granted 318,995 options to buy @ $2.66, valued at $848.5k
01/24/2023 4 Wang Yizhe (CEO) has filed a Form 4 on LianBio
Txns: Granted 1,292,324 options to buy @ $2.66, valued at $3.4M
01/05/2023 4 QIAN JIANG (SVP, China General Manager) has filed a Form 4 on LianBio
Txns: Sold 2,239 shares @ $1.6532, valued at $3.7k
12/19/2022 8-K Quarterly results
12/13/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "LianBio Announces President and Chief Strategy Officer Departure"
12/09/2022 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
11/14/2022 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in LianBio
10/12/2022 8-K Other Events  Interactive Data
08/22/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
06/27/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/27/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy